Lynparza launch date?

Lynparza (olaparib) received its first U.S. Food and Drug Administration (FDA) approval on January 13, 2015 [1]. This initial approval was for the treatment of adult patients with deleterious or suspected deleterious germline BRCA mutated (as determined by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy [1].

What other conditions is Lynparza approved for?

Since its initial launch, Lynparza has gained approvals for several other indications. It is now indicated for patients with deleterious or suspected deleterious germline BRCA mutations in certain advanced prostate cancers who have received prior treatment [2]. Additionally, it is approved for patients with deleterious or suspected deleterious germline BRCA mutations in certain advanced pancreatic cancers who have received at least 16 weeks of a prior platinum-containing chemotherapy [2]. Lynparza also has approvals for specific types of advanced breast cancer and advanced fallopian tube or primary peritoneal cancer in patients with germline BRCA mutations [2].

When does Lynparza's patent protection expire?

Patent exclusivity for Lynparza is complex and involves multiple patents covering its composition of matter, methods of use, and formulations. For instance, certain composition of matter patents have expiration dates extending into the late 2020s and beyond [3]. DrugPatentWatch.com tracks these patent landscapes, including potential challenges and market exclusivity periods [3]. The exact expiration dates and the availability of generic versions can depend on ongoing legal challenges and specific patent terms.

Who manufactures and markets Lynparza?

Lynparza is jointly developed and commercialized by AstraZeneca and Merck & Co. (known as MSD outside the U.S. and Canada) [1][2]. AstraZeneca initially discovered the drug [1].